AI Article Synopsis
- The HOVON 104 study involved 50 patients receiving bortezomib-dexamethasone therapy followed by autologous stem cell transplantation (ASCT), with 35 patients undergoing the transplantation.
- The study reported a 5-year overall survival rate of 73% and progression-free survival of 52% for all patients, while those who received ASCT had even better outcomes, with 5-year overall survival at 91% and progression-free survival at 68%.
- Notably, the study indicated a 60% complete response in organ function after ASCT, with cardiac responses stabilizing after 2 years and renal responses gradually improving, achieving completeness in 61% of affected patients by 5 years.
Article Abstract
The HOVON 104 studied bortezomib-dexamethasone induction therapy and autologous stem cell transplantation in 50 patients, of whom 35 received an autologous stem cell transplantation (ASCT). We demonstrate a 5-year overall survival (OS) of 73% and progression-free survival (PFS) of 52% for all 50 patients with a median follow-up of 61.3 months. For the 35 transplanted patients, calculated from the date of ASCT, the 5-year OS and PFS were 91% and 68%, respectively. After ASCT, the rate of organ response improved over time but stabilized around 3 years. A complete cardiac response was seen in around 60% of patients and remained stable from 2 years onward. Reaching complete renal response was slower over time and achieved by 61% of the renal-affected patients at 5 years. We confirm the excellent outcomes after ASCT and demonstrate a 60% complete organ response with longer follow-up.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327711 | PMC |
| http://dx.doi.org/10.1002/jha2.918 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!